Similar articles for PMID: 31704274

Year	Number of Results
1999	1
2001	1
2003	2
2004	2
2005	2
2006	1
2007	5
2008	1
2009	3
2010	4
2011	3
2012	4
2013	4
2014	5
2015	11
2016	12
2017	13
2018	12
2019	13
2020	11
2021	7
2022	14
2023	9
2024	0

1

Disease-modifying strategies in primary tauopathies.

Rösler TW, Costa M, Höglinger GU. Rösler TW, et al. Neuropharmacology. 2020 May 1;167:107842. doi: 10.1016/j.neuropharm.2019.107842. Epub 2019 Nov 5. Neuropharmacology. 2020. PMID: 31704274 Review.

2

A walk through tau therapeutic strategies.

Jadhav S, Avila J, Schöll M, Kovacs GG, Kövari E, Skrabana R, Evans LD, Kontsekova E, Malawska B, de Silva R, Buee L, Zilka N. Jadhav S, et al. Acta Neuropathol Commun. 2019 Feb 15;7(1):22. doi: 10.1186/s40478-019-0664-z. Acta Neuropathol Commun. 2019. PMID: 30767766 Free PMC article. Review.

3

Tauopathies as clinicopathological entities.

Irwin DJ. Irwin DJ. Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1(0 1):S29-33. doi: 10.1016/j.parkreldis.2015.09.020. Epub 2015 Sep 8. Parkinsonism Relat Disord. 2016. PMID: 26382841 Free PMC article. Review.

4

An Overview on the Clinical Development of Tau-Based Therapeutics.

Medina M. Medina M. Int J Mol Sci. 2018 Apr 11;19(4):1160. doi: 10.3390/ijms19041160. Int J Mol Sci. 2018. PMID: 29641484 Free PMC article. Review.

5

Tau phosphorylation and aggregation as a therapeutic target in tauopathies.

Badiola N, Suárez-Calvet M, Lleó A. Badiola N, et al. CNS Neurol Disord Drug Targets. 2010 Dec;9(6):727-40. doi: 10.2174/187152710793237403. CNS Neurol Disord Drug Targets. 2010. PMID: 20942789 Review.

6

Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies.

Fuster-Matanzo A, Hernández F, Ávila J. Fuster-Matanzo A, et al. Int J Mol Sci. 2018 Feb 25;19(3):645. doi: 10.3390/ijms19030645. Int J Mol Sci. 2018. PMID: 29495325 Free PMC article. Review.

7

Brain microRNAs dysregulation: Implication for missplicing and abnormal post-translational modifications of tau protein in Alzheimer's disease and related tauopathies.

Bazrgar M, Khodabakhsh P, Mohagheghi F, Prudencio M, Ahmadiani A. Bazrgar M, et al. Pharmacol Res. 2020 May;155:104729. doi: 10.1016/j.phrs.2020.104729. Epub 2020 Feb 29. Pharmacol Res. 2020. PMID: 32126270 Review.

8

Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Josephs KA. Josephs KA. Mayo Clin Proc. 2017 Aug;92(8):1291-1303. doi: 10.1016/j.mayocp.2017.04.016. Mayo Clin Proc. 2017. PMID: 28778262 Free PMC article. Review.

9

Frontotemporal dementia with tau pathology.

Gasparini L, Terni B, Spillantini MG. Gasparini L, et al. Neurodegener Dis. 2007;4(2-3):236-53. doi: 10.1159/000101848. Neurodegener Dis. 2007. PMID: 17596718 Review.

10

Tauopathies.

Hernández F, Avila J. Hernández F, et al. Cell Mol Life Sci. 2007 Sep;64(17):2219-33. doi: 10.1007/s00018-007-7220-x. Cell Mol Life Sci. 2007. PMID: 17604998 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

128 results

Results by year